XL t(15;17) DF consists of an orange-labeled probe hybridizing to the PML gene region at 15q24 and a green-labeled probe hybridizing to the RARA gene region at 17q21.1-21.2.

Probe maps for selected products have been updated. These updates ensure a consistent presentation of all gaps larger than 10 kb including adjustments to markers, genes, and related elements. This update does not affect the device characteristics or product composition. Please refer to the list to find out which products now include updated probe maps.

Probe map details are based on UCSC Genome Browser GRCh37/hg19, with map components not to scale.

Several recurrent balanced translocations and inversions, and their variants, are recognized in the WHO category acute myeloid leukemia (AML) with recurrent genetic abnormalities. Furthermore, several cytogenetic abnormalities are considered sufficient to establish the WHO diagnosis of AML with myelodysplasia-related features if 20% or more blood or marrow blasts are present.

AML M3 and AML M3v are characterized by a reciprocal translocation between the long arm of chromosome 15 and the long arm of chromosome 17. This translocation leads to a rearrangement of the PML gene situated on chromosomal band 15q24 and the RARA gene situated on band 17q21. The PML-RARA rearrangement has gained major clinical importance because, in combination with all-trans retinoic acid (ATRA) and conventional anthracycline and cytarabine based chemotherapy, it leads to an improved prognosis in this subgroup of AML.

Clinical Applications

• Acute Myelogenous Leukemia (AML)

XL t(15;17) DF hybridized to bone marrow cells. One orange, one green, and two fusion signals each are observed in the interphase nuclei indicating the presence of t(15;17).

• Grimwade et al (2000) Blood 96:1297-1308
• Schoch et al (2002) Hematol J 3:259-263
• Campbell et al (2013) BioMed Res Int: Article ID 164501